Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Arm Phase 2 Study of Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women with Hormone Receptor-Negative, HER2-Negative Early Stage/Resectable Breast Cancer.

Next Previous
Trial Profile

A Single Arm Phase 2 Study of Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women with Hormone Receptor-Negative, HER2-Negative Early Stage/Resectable Breast Cancer.

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Capecitabine; Olaparib
  • Indications Carcinoma; Early breast cancer; HER2 negative breast cancer; Triple negative breast cancer
  • Focus Therapeutic Use

Most Recent Events

  • 24 Jul 2024 Planned End Date changed from 1 Jun 2026 to 1 Jun 2028.
  • 24 Jul 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Jun 2026.
  • 15 Sep 2023 The study protocol amended to add pembrolizumab as an alternative ICI option in treatment arms. Inclusion and exclusion criteria also changed for the same.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top